Brief: Paion AG says Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial
28/06/2017 19:34
June 28 (Reuters) - Paion Ag PA8G.DE :
* Positive headline data in U.S. Phase III trial with
Remimazolam for procedural sedation undergoing bronchoscopy
* Primary efficacy endpoint successfully achieved
* Remimazolam met its primary efficacy endpoint in U.S.
Phase III clinical trial in procedural sedation in patients
undergoing bronchoscopy
Source text for Eikon: ID:nEQ4NRdh7a
Further company coverage: PA8G.DE
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022